Introduction: Sleep disorder may have detrimental consequences on health and one of the treatments is the use of hypnotics. Unfortunately, hypnotics treatment may also be accompanied by side effects and lead to dependence. The present study aimed to investigate the sleep improving effects of ethanol extract of Gardenia augusta (L.) Merr. flowers in rat model. Methods: Rats were assigned into group receiving the extract (at 0.9 or 1.8 g/kg), the reference drug crocetin (at 0.9 mg/kg) or vehicle, once a day orally for 15 days. Results: Tested on day 1 and 14 of treatment, the rats receiving 1.8 g/kg of the extract showed improvements in sleep latency, sleep duration, sleep efficiency, wake episodes, and sleep cycle, which were significantly different from crocetin. Furthermore, tested on day 2 and 15 of treatment, the rats treated with 1.8 g/kg extract demonstrated superior sedative rating scale compared to crocetin. Conclusions: Results of the present study indicates the potential of Gardenia augusta (L.) Merr. flower extract to be used as an adjunct treatment for sleep disorder.
INTRODUCTION
Sleep disorder has become a global issue that has to be taken into consideration seriously. The World Health Organization has reported that in Asian and African regions 16.9% adults had serious sleep problem with the increase in prevalence ranged from 3.9% (Indonesia and Kenya) to 40% (Bangladesh). In addition, from the eight surveyed countries, the problem was more prevalent in women and elderly than in men. 1 One of the most prevalent sleep disorders is insomnia, which is characterized by disturbed sleep onset and sleep maintenance, or poor quality sleep, rendering the impairment of functioning in the following days, with the possible ensuing psychological distress. 2, 3 The first treatment of sleep disorder or decreased quality sleep should be nonpharmacological measures. However, when this method does not work, pharmacological treatment may be needed which include the use of hypnotic drugs. Unfortunately, the use of this class of drug poses the users to the risk of dependence and its detrimental sequelae. Early works have been carried out to test the effects of supplements in an effort to prevent the risk. Thus, Attelle and co-workers 4 have suggested the use of herbals and amino acids. Corroborating this suggestion, Ziegler and collaborators 5 as well as Yamadera and colleagues 6 have demonstrated sleep ameliorating activity of valerian and glycine. Additionally, there has been a thorough review that indicates the potential of herbals to treat sleep disorder, with the GABA-ergic system as the proposed target brain substrate. 7
One of the medicinal plants suggested to have sleep-improving activity is Gardenia augusta. 8, 9 Gardenia augusta, which belongs to the family of Rubiaceae, originated in Asia. The plant is called zhi zhi in China and kuchinashi in Japan. In both countries the yellow flowers are used as dye for cloth and food. Meanwhile, the white, large flowers are highly fragrant. 10 The plant has been shown to contain several chemical constituents, including crocetin, crocin, 11 geniposide and genipin. 12 Being an oriental medicine, Gardenia is used to treat inflammation, jaundice, headache, edema, fever, hepatic disorders, and hypertension. 13 Several preclinical studies have further demonstrated the pharmacological properties of active ingredients contained in Gardenia. Crocin and crocetin were shown to have pancreatic lipase inhibiting activity. 14 Crocin was also shown to have antioxidant property. 15, 16 Geniposide was found to have antiangiogenic and neuroprotective activities. 17, 18 Geniposide and other ingredient isolated from the fruit, genipin, also demonstrated anti-inflammatory property. 19 In the present study, we investigated the sleepimproving effect of ethanol extract of the flowers of Gardenia augusta (L.) Merr. The possible effect was compared to crocetin, a secondary metabolite contained in Gardenia, previously demonstrated to have ameliorating effect on sleep disorder.
MATERIALS AND METHODS

Plant materials and drugs
Crude drug was prepared from the plant Gardenia augusta (L.) Merr. collected from Manoko botanical garden in the Northern part of Bandung Indonesia. The plant was determined for identification in Herbarium Bandungense, School of Life Sciences and Technology, Institut Teknologi Bandung. Dried ground raw materials were refluxed with 96% ethanol. The extract obtained was then concentrated using rotary evaporator (Buchi, Flawil Switzerland). The concentrated extract was prepared to make test doses of 0.9 and 1.8 g/kg. Crocetin was purchased from Sigma. All the substances were dispersed in 0.3% Sodium-CMC and were given orally at 0.1 ml/100 kg of body weight, once a day for 15 days.
Animals
Male Wistar rats (150-200 g) supplied by Animal Laboratory of School of Pharmacy Institut Teknologi Bandung were used. The animals were acclimatized for one week before the experiments. They were kept at constant ambient temperature of 25 o C under 12-h light/dark cycle with free access to food and water except during observations. The rats were assigned into four groups of 6 each, treated with 0.3% Sodium-CMC, 0.9 g/kg extract, 1.8 g/kg extract, and 0.9 mg/kg crocetin, respectively. Procedures for animal handling have been approved by the committee of laboratory animal use and care, Faculty of Medicine Padjadjaran University, Bandung, Indonesia (Certificate of Approval No 07/UN6. KEP/EC/2018), which is in line with the principle of replacement, refinement and reduction of animal use in research.
Sleep latency
Sleep latency was defined as the period between test substance administration and the time the rats started to fall asleep. The latency was determined on day 1 and 14 of treatment, confirmed with thermal camera (FLIR E5) to observe changes in brain as well as dorsal temperatures.
Sleep duration
Sleep duration was defined as duration of sleep after administration of test substance. The measurement, performed on day 1 and 14 of treatment, was confirmed by using thermal camera to observe changes in brain and dorsal temperatures.
Sleep efficiency
The sleep efficiency was calculated using data of sleep duration and latency, using the following formula,
Sleep efficiency (%) = Sleep duration / (Sleep latency + Sleep duration)
Wake episodes
Wake episode was defined as the amount of waking during sleeping period. Recorded on day 1 and 14 of treatment, this parameter was confirmed using thermal camera to observe changes in brain as well as dorsal temperatures.
Sleep cycle
Sleep cycle was determined using thermal camera on day 1 and 14 of treatment. The cycle was defined as a condition in which alteration between decrease (NREM) and increase (REM) in brain and dorsal temperatures took place.
Sedative effect
The sedative effect, observed on day 2 and 15 of treatment, was measured based on assessment on sedation rating scale. The rating measured the scale between 0 to 5, with 0=sleeping characterized by eyes fully closed, relaxed body, 1=severe sedation marked by closed eyes, loss of righting reflex, 2=head partly or completely down, eyes partly closed, flat posture, no spontaneous movement, 3=eyes partially closed, head somewhat down, movement disturbance, abnormal posture, limbs partially used, dragging and stumble, 4=eyes fully open, head up, no or limited movement, rearing or grooming, normal posture, 5=active movement, rearing, head movement or grooming.
Statistical analysis
Experimental data are presented as means + SD. Significance of difference between groups was determined using One-way ANOVA for the comparison of sleep quality among treatment groups, paired student t-test for comparing sleep quality observed at day 1 and 14, and Kruskal-Wallis to compare data represented in sedation rating scale. A difference was considered significant at p<0.05.
RESULTS
Sleep latency
As shown in Figure 1 , the sleep latencies on day 1 for group of mice receiving 0.9 and 1.8 g/kg were 138.83 ± 45.04 mins and 87.0 ± 20.43 mins, respectively which were significantly different from that of the vehicle-treated group that was 201.33 ± 25.46 (p<0.05). On day 14 the latencies were 136.67 ± 38.69 and 80.83 ± 27.46 mins, respectively, significantly different (p<0.05) from the value of the vehicle-treated group which was 197.50 ± 33.73 mins. While the latency observed in group receiving 0.9 g/kg extract was not significantly different from that treated with the reference drug crocetin, the sleep latency in group receiving test substance at 1.8 g/kg was significantly shorter compared to that in crocetin group.
Sleep duration
Results on the effect of the extract on sleep duration are shown in Figure 2 . On day 1, the duration in groups receiving 0.9 and 1.8 g/kg extract were 332.33 ± 39.83 mins and 374.67 ± 20.43 mins, respectively which were significantly different compared to that of vehicle-treated group (p<0.05) with the duration of 252.33 ± 25.19 mins. Meanwhile, on day 14, the respective durations of groups treated with 0.9 and 1.8 g/kg extract were 332.50 ± 39.72 mins and 387.0 ± 28.06 mins, which were significantly different from that of control of 276.67 ± 22.52 mins. Sleep duration in group receiving 0.9 g/kg extract was comparable to that in group receiving the reference substance crocetin, however the duration observed in 1.8 g/kg extract-treated group was significantly longer than that of the crocetin group. Figure 3 demonstrates the results on sleep efficiency. As the figure shows, on day 1, the efficiencies in the groups treated with 0.9 and 1.8 g/kg extract were 70.74 ± 8.05% and 81.11 ± 4.13%, respectively, significantly different (p<0.05) from that in group treated with vehicle whose value was 55.62 ± 5.56%. On day 14, the respective efficiencies of the groups were 70.86 ± 8.18 % and 82.75 ± 5.82 %, significantly higher than 58,47 ± 6.00% of the vehicle-treated group (p<0.05). While the efficiency shown by the 0.9 g/kg extract-treated group was comparable to that of the reference substance crocetin, the sleep efficiency in group treated with 1.8 g/kg extract was significantly higher than that of 0.9 g/ kg extract or crocetin-treated group.
Sleep efficiency
Wake episodes
Results on the wake episodes are described in Figure 4 . On day 1 the episodes in groups receiving 0.9 and 1.8 g/kg extract were 7.17 ± 1.69 and 4.20 ± 1.82, respectively, significantly lower (p<0.05) compared to that in vehicle-treated group which had the value of 12.33 ± 2.73. On day 14 the episodes in groups receiving 0.9 and 1.8 g/kg extract were 6.85 ± 2.02 and 3.48 ± 1.43, respectively, which were also significantly lower compared to that in vehicle-treated group with the value of 11.50 ± 2.47. The wake episode in group treated with 0.9 g/kg extract was comparable to that observed in group receiving the reference substance crocetin (with respective values of 7.27 ± 2.86 and 7.30 ± 1.76 on day 1 and 14). Meanwhile, the figure was significantly lower (p<0.05) in group treated with 1.8 g/kg extract compared to crocetin-treated group. Figure 5 depicts the results on the number of sleeping cycle. It was shown that the cycles were significantly lower (p<0.05) in groups treated with the test doses of the extract as well as the reference substance crocetin. On day 1 the number of cycles in group treated with 0.9 and 1.8 g/kg extract and vehicle-treated group were 4 ± 0.63, 4.5 ± 1.05, and 6.33 ± 0.82, respectively. Meanwhile, the respective figures on day 14 were 4 ± 0.63, 3.67 ± 1.51, and 6 ± 0.89. No significant difference was observed in the number of cycle among the group treated with extracts and crocetin.
Sleep cycle
Sedative effect
Results on the sedation rating scale are shown in Figure 6 . Significant differences in sedation rating scale among treatment groups were observed both on days 2 and 15 (respective Kruskal-Wallis were 14.94 and 15.25, and both days had p<0.05). While the score in group receiving 0.9 g/kg extract was not significantly different from that in crocetin-treated group, the score in group receiving 1.8 g/kg extract was significantly lower compared to the crocetin group.
DISCUSSION
The present study investigated the effect of flower extract of the plant Gardenia augusta (L.) Merr. in rat model. Earlier studies have demonstrated the components of this plant contained metabolite showing the activity to improve the quality of sleep. While flowers are often regarded as waste after they fall to the ground, or used as a decorative component, mostly the plant part studied for the biological activities was the fruits. [20] [21] [22] [23] [24] To the best of our knowledge, the present study was the first one which focused on investigating the effect of flower extract of the plant on sleep improvement.
The extract was shown to dose-dependently improve the sleep quality with the highest dose of 1.8 g/kg being superior compared to the reference drug crocetin. The test doses of 0.9 and 1.8 mg/kg extract were selected based on the result of an unpublished preliminary data that showed potentiating effect Gardenia flower ethanol extract on phenobarbital-induced hypnosis. The characteristic of effect of the flower extract resembled that of crocetin, isolated from the Gardenia fruits. While it has not been confirmed the possible active ingredient responsible for the activity at this stage, judging from the present results, one may suggest that the substance at least in part had the similarity with crocetin, which was used as reference substance in the present study.
We found the effective dose of the flower extracts being somewhat on the high side, as the results showed that the dose of 1.8 g/kg had the activity which exceeded that of the reference substance crocetin, given at a dose of as low as 0.9 mg/kg. This finding might be attributable to the content of the active substance. As reported by Gao and Zhu, 25 crocin, a substance having crocetin in its core, accumulates during fruit maturation, long after blossoming. Furthermore, pharmacokinetic study of crocin in rats revealed that following administration of crocin, only small amount of crocetin, as metabolite of crocin, was found in the blood. 26 Results of the work of Gao dan Zhu 25 specifically demonstrated that crocetin content escalated over time, peaking at stage 4 of fruit development, and no crocetin content found at stage 1. In terms the other psychoactive component geniposide, however, its content was almost constant even before fruit development. Earlier study by Choi and co-workers 27 indicated that geniposide exerted the increase in Clinflux in neuroblastoma, resembling GABA-ergic activation. Taking this data into consideration, one may further suggest that geniposide could be the component of the extract used in our present study, responsible for the sleep-improving effect, as crocin has been shown to be absent at the flowering stage. Interestingly, however, behavioral study failed to show locomotor-suppressing activity of geniposide. The data, thus, points to the possibility of different component which might be contained in the petal of the Gardenia flower with sleep-improving activity. In this respect, substances as revealed by Zhang and co-workers 28 in the Gardenia flower could be the potential candidate for the ones with the sleep-improving activity.
Sleeping disorder has been indicated to have adverse consequences economically. Albeit unknown outcome of the untreated insomnia, detrimental health outcomes have been recognized to accompany the sleep disorder that include poor quality of life. 29, 30 Walsh 3 has demonstrated that direct costs for the management of insomnia have been estimated to be USD13.9 billion annually, and successful treatment of insomnia has been indicated to be correlated with direct cost savings and improved quality of life. 31 However, the saving observed from the latter study seemed not so significant, probably due to additional expenses that might arise from the psychoactive nature of most medications for the treatment of sleep disorder. The use of safe and effective plant-derived substances to manage sleep disorder might have additional benefits economically.
Results of the present study did not show potential adverse effects of Gardenia flower extract, even when the extract was administered at the dose of as high as 1.8 g/kg. No matter how safe the extract seems, however, detailed safety assessment on the extract is required.
CONCLUSION
The present study demonstrated that the flowers of the plant Gardenia augusta (L.) Merr. has sleep-improving activity, further confirming earlier studies and the practice of using the Gardenia plant as an alternative in treating insomnia. At the moment, it is suggested that high doses of the extract are needed for the activity, however, further studies which could be done to pinpoint the exact component responsible for the activity might corroborate the use of flowers of Gardenia, part of the plant often neglected, to be used to combat sleep disorder. Figure 6 : Effects of ethanol extract of Gardenia augusta (L.) Merr. leaves on sedation rating scales in rats. The scales, based on the level of behavior suppression, ranging from 0 (highly suppressed) to 5 (normal behavior) were recorded for 2 mins. Data represent the average+SD of the scale, collected on days 2 and 15 of treatment, with 6 rats per group. α,β,δ p<0.05 compared with vehicle, crocetin (0.9 mg/kg), and 1.8 g/kg extract, respectively.
